secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001651308-23-000137
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene regains full global rights to tislelizumab after terminating Novartis license agreement
--------------------------------------------------------------------------------

- On September 17, 2023, BeiGene Switzerland and Novartis mutually terminated the Collaboration and License Agreement for tislelizumab, effective immediately.
- BeiGene regains full global rights to develop, manufacture, and commercialize tislelizumab with no royalty payments due to Novartis.
- Novartis may continue ongoing clinical trials and conduct future combination trials with tislelizumab subject to BeiGene's approval.
- Novartis will provide transition services including manufacturing, regulatory, safety, and clinical support for tislelizumab.
- The termination covers licensed territories: US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/0001651308-23-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/bgne-20230917.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer